Mepact (Mifamurtide)

• Mepact (mifamurtide) is used in the management of bone‑derived malignancies, specifically high‑grade osteosarcoma.
• High‑grade resectable non‑metastatic osteosarcoma: improves event‑free survival when combined with standard chemotherapy in patients ≥2 years.
• Localized osteosarcoma after complete surgical resection: provides immunostimulatory support to reduce recurrence risk.
• Adjuvant therapy for osteosarcoma in pediatric and adolescent patients: integrates with multi‑agent regimens to target microscopic disease.

• Mifamurtide is a synthetic lipophilic derivative of a bacterial cell wall component that activates the intracellular NOD2 (nucleotide‑binding oligomerization domain‑containing protein 2) receptor in monocytes and macrophages. This triggers NF‑κB signaling, leading to the release of pro‑inflammatory cytokines and chemokines that enhance the innate immune response and promote tumor‑cell phagocytosis and apoptosis. The amplified immune activation also up‑regulates antigen presentation, facilitating adaptive immune mechanisms against malignant bone cells.

Mepact may be associated with a range of adverse reactions, which are generally categorized by frequency and severity.

Common Side Effects

• Fever: transient elevation of body temperature often occurring shortly after infusion.
• Nausea: mild to moderate feeling of queasiness.
• Vomiting: occasional episodes post‑infusion.
• Fatigue: generalized tiredness during treatment course.

Serious or Rare Side Effects

• Hypotension: sudden drop in blood pressure requiring medical attention.
• Anaphylaxis: severe allergic reaction with respiratory distress and urticaria.
• Hepatotoxicity: elevated liver enzymes indicating potential liver injury.

When using Mepact, clinicians should observe several precautionary measures to ensure patient safety and product integrity.

• Monitoring: Perform regular assessment of vital signs, especially during and after infusion.
• Liver Function: Check hepatic enzymes before each cycle and adjust therapy if significant elevation occurs.
• Cardiovascular: Observe for signs of hypotension or arrhythmia during administration.
• Concomitant Therapy: Evaluate potential interactions with other immunomodulatory or cytotoxic agents.
• Pregnancy and Lactation: Use only if potential benefit justifies potential risk; data are limited.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Mepact can interact with other medicines, influencing its efficacy or safety profile.

Major Interactions (Avoid)

• Live Vaccines: concurrent use may increase risk of severe infection due to immune modulation.
• High‑dose Corticosteroids: may blunt the immunostimulatory effect of mifamurtide.
• Anticoagulants: increased bleeding risk if infusion causes thrombocytopenia.

Moderate Interactions (Monitor Closely)

• Other Immunotherapies: combined immune activation may raise incidence of cytokine‑release symptoms.
• Hepatotoxic Drugs: concurrent use may exacerbate liver enzyme elevations.
• NSAIDs: may mask fever, a key indicator of infusion reaction.